Ken A. Saunders

Ken A. Saunders

Auto-generated profile, based on publicly available information

Ken A. Saunders

Immunology Research Unit, GSK, Stevenage, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MTMartha Triantafilou
Martha Triantafilou
JRJoshi Ramanjulu
Joshi Ramanjulu
LBLee Booty
Lee Booty
GJGisela Jimenez-Duran
Gisela Jimenez-Duran
HKHakan Keles
Hakan Keles
KTKathy Triantafilou
Kathy Triantafilou
Human rhinovirus (HRV), like coronavirus (HCoV), are positive-strand RNA viruses that cause both upper and lower respiratory tract illness, with their replication facilitated by concentrating RNA-synthesizing machinery in intracellular compartments made of modified host membranes, referred to as replication organelles (ROs). Here we report a non-canonical, essential function for stimulator of interferon genes (STING) during HRV infections. While the canonical function of STING is to detect cytosolic DNA and activate inflammatory responses, HRV infection triggers the release of STIM1-bound STING in the ER by lowering Ca2+, thereby allowing STING to interact with phosphatidylinositol 4-phosphate (PI4P) and traffic to ROs to facilitates viral replication and transmission via autophagy. Our results thus hint a critical function of STING in HRV viral replication and transmission, with possible implications for other RO-mediated RNA viruses.

19 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MAMark Almond
Mark Almond
HFHugo A. Farne
Hugo A. Farne
MJMillie M. Jackson
Millie M. Jackson
AJAkhilesh Jha
Akhilesh Jha
OKOrestis Katsoulis
Orestis Katsoulis
ASAran Singanayagam
Aran Singanayagam
Obesity is a well-recognized risk factor for severe influenza infections but the mechanisms underlying susceptibility are poorly understood. Here, we identify that obese individuals have deficient pulmonary antiviral immune responses in bronchoalveolar lavage cells but not in bronchial epithelial cells or peripheral blood dendritic cells. We show that the obese human airway metabolome is perturbed with associated increases in the airway concentrations of the adipokine leptin which correlated negatively with the magnitude of ex vivo antiviral responses. Exogenous pulmonary leptin administration in mice directly impaired antiviral type I interferon responses in vivo and ex vivo in cultured airway macrophages. Obese individuals hospitalised with influenza showed dysregulated upper airway immune responses. These studies provide insight into mechanisms driving propensity to severe influenza infections in obesity and raise the potential for development of leptin manipulation or interferon administration as novel strategies for conferring protection from severe infections in obese higher risk individuals.

1 November 2021 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Open access
SWSabine Wronski
Sabine Wronski
SBSoren Beinke
Soren Beinke
HOHelena Obernolte
Helena Obernolte
NBNikolai N. Belyaev
Nikolai N. Belyaev
KSKen A. Saunders
Ken A. Saunders
OGOn behalf of the U-BIOPRED Study Group
On behalf of the U-BIOPRED Study Group
Human rhinovirus (RV) is a major risk factor for chronic obstructive pulmonary disease (COPD) and asthma exacerbations. The exploration of RV pathogenesis has been hampered by a lack of disease-relevant model systems. We performed a detailed characterization of host responses to RV infection in human lung tissue ex vivo and investigated whether these responses are disease relevant for patients with COPD and asthma. In addition, impact of the viral replication inhibitor rupintrivir was evaluated. Human precision-cut lung slices (PCLS) were infected with RV1B with or without rupintrivir. At Days 1 and 3 after infection, RV tissue localization, tissue viability, and viral load were determined. To characterize host responses to infection, mediator and whole genome analyses were performed. RV successfully replicated in PCLS airway epithelial cells and induced both antiviral and proinflammatory cytokines such as IFNα2a, CXCL10, CXCL11, IFN-γ, TNFα, and CCL5. Genomic analyses revealed that RV not only induced antiviral immune responses but also triggered changes in epithelial cell–associated pathways. Strikingly, the RV response in PCLS was reflective of gene expression changes described in patients with COPD and asthma. Although RV-induced host immune responses were abrogated by rupintrivir, RV-triggered epithelial processes were largely refractory to antiviral treatment. Detailed analysis of RV-infected human PCLS and comparison with gene signatures of patients with COPD and asthma revealed that the human RV PCLS model represents disease-relevant biological mechanisms that can be partially inhibited by a well-known antiviral compound and provide an outstanding opportunity to evaluate novel therapeutics.

1 October 2012 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
DCDavid Clapham
David Clapham
DKDmitry Kirsanov
Dmitry Kirsanov
ALAndrei Legin
Andrei Legin
Alisa RudnitskayaAlisa Rudnitskaya
Alisa Rudnitskaya
KSKen Saunders
Ken Saunders

1 January 2013 in Journal of Cell Science
Verified
Journal Article
Closed access
PDF file
PTPeter J. Trebble
Peter J. Trebble
JWJames M. Woolven
James M. Woolven
KSKen A. Saunders
Ken A. Saunders
KSKaren D. Simpson
Karen D. Simpson
SFStuart N. Farrow
Stuart N. Farrow
DRDavid Ray
David Ray
The ubiquitously expressed glucocorticoid receptor (GR) is a major drug target for inflammatory disease, but issues of specificity, and target tissue sensitivity remain. We now identify high potency, non-steroidal GR ligands, GSK47867A and GSK47869A, which induce a novel conformation of the GR ligand binding domain (LBD) and augment the efficacy of cellular action. Despite their high potency GSK47867A and GSK47869A both induce surprisingly slow GR nuclear translocation, followed by prolonged nuclear GR retention, and transcriptional activity following washout. We reveal that GSK47867A and GSK47869A specifically alter the GR LBD structure at the HSP90 binding site. The alteration in HSP90 binding site was accompanied by resistance to HSP90 antagonism, with persisting transactivation seen after geldanamycin treatment. Taken together, our studies reveal a novel mechanism governing GR intracellular trafficking regulated by ligand binding, which relies on a specific surface charge patch within the LBD. This conformational change permits extended GR action, likely due to altered GR-HSP90 interaction. This chemical series may offer anti-inflammatory drugs with prolonged duration of action due to altered pharmacodynamics rather than altered pharmacokinetics.

24 April 2017 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
PPPanayiotis A. Procopiou
Panayiotis A. Procopiou
AFAlison J. Ford
Alison J. Ford
PGPaul M. Gore
Paul M. Gore
BLBrian E. Looker
Brian E. Looker
SHSimon T. Hodgson
Simon T. Hodgson
CWClarissa J. Watts
Clarissa J. Watts